vs
Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and Axil Brands, Inc. (AXIL). Click either name above to swap in a different company.
Aquestive Therapeutics, Inc. is the larger business by last-quarter revenue ($13.0M vs $8.1M, roughly 1.6× Axil Brands, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -244.8%, a 253.5% gap on every dollar of revenue. On growth, Aquestive Therapeutics, Inc. posted the faster year-over-year revenue change (9.7% vs 5.2%). Axil Brands, Inc. produced more free cash flow last quarter ($906.4K vs $-8.6M). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs 3.9%).
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
AQST vs AXIL — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.0M | $8.1M |
| Net Profit | $-31.9M | $704.9K |
| Gross Margin | 55.2% | 68.1% |
| Operating Margin | -221.6% | 11.1% |
| Net Margin | -244.8% | 8.7% |
| Revenue YoY | 9.7% | 5.2% |
| Net Profit YoY | -86.8% | 11.2% |
| EPS (diluted) | $-0.26 | $0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.0M | $8.1M | ||
| Q3 25 | $12.8M | $6.9M | ||
| Q2 25 | $10.0M | $5.8M | ||
| Q1 25 | $8.7M | $6.9M | ||
| Q4 24 | $11.9M | $7.7M | ||
| Q3 24 | $13.5M | $5.9M | ||
| Q2 24 | $20.1M | $6.5M | ||
| Q1 24 | $12.1M | $6.5M |
| Q4 25 | $-31.9M | $704.9K | ||
| Q3 25 | $-15.4M | $334.3K | ||
| Q2 25 | $-13.5M | $-245.6K | ||
| Q1 25 | $-22.9M | $576.7K | ||
| Q4 24 | $-17.1M | $633.7K | ||
| Q3 24 | $-11.5M | $-109.8K | ||
| Q2 24 | $-2.7M | $49.5K | ||
| Q1 24 | $-12.8M | $781.1K |
| Q4 25 | 55.2% | 68.1% | ||
| Q3 25 | 64.8% | 67.6% | ||
| Q2 25 | 54.4% | 70.0% | ||
| Q1 25 | 58.1% | 71.7% | ||
| Q4 24 | 61.9% | 71.1% | ||
| Q3 24 | 67.2% | 71.0% | ||
| Q2 24 | 77.5% | 71.5% | ||
| Q1 24 | 63.6% | 71.5% |
| Q4 25 | -221.6% | 11.1% | ||
| Q3 25 | -89.6% | 6.0% | ||
| Q2 25 | -113.6% | 0.8% | ||
| Q1 25 | -222.1% | 8.4% | ||
| Q4 24 | -114.4% | 8.7% | ||
| Q3 24 | -61.2% | -2.4% | ||
| Q2 24 | 0.3% | 2.6% | ||
| Q1 24 | -74.3% | -1.6% |
| Q4 25 | -244.8% | 8.7% | ||
| Q3 25 | -120.6% | 4.9% | ||
| Q2 25 | -135.4% | -4.3% | ||
| Q1 25 | -263.0% | 8.3% | ||
| Q4 24 | -143.7% | 8.2% | ||
| Q3 24 | -85.0% | -1.9% | ||
| Q2 24 | -13.7% | 0.8% | ||
| Q1 24 | -106.4% | 12.1% |
| Q4 25 | $-0.26 | $0.09 | ||
| Q3 25 | $-0.14 | $0.04 | ||
| Q2 25 | $-0.14 | $-0.03 | ||
| Q1 25 | $-0.24 | $0.07 | ||
| Q4 24 | $-0.18 | $0.08 | ||
| Q3 24 | $-0.13 | $-0.02 | ||
| Q2 24 | $-0.03 | $0.11 | ||
| Q1 24 | $-0.17 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $5.0M |
| Total DebtLower is stronger | $27.5M | $138.3K |
| Stockholders' EquityBook value | $-33.7M | $11.1M |
| Total Assets | $160.4M | $16.2M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.0M | ||
| Q3 25 | $129.1M | $4.1M | ||
| Q2 25 | $60.5M | $4.8M | ||
| Q1 25 | $68.7M | $4.7M | ||
| Q4 24 | $71.5M | $5.2M | ||
| Q3 24 | $77.9M | $4.1M | ||
| Q2 24 | $89.9M | $3.3M | ||
| Q1 24 | $95.2M | $4.9M |
| Q4 25 | $27.5M | $138.3K | ||
| Q3 25 | $45.0M | $139.2K | ||
| Q2 25 | $45.0M | $140.2K | ||
| Q1 25 | $45.0M | $141.0K | ||
| Q4 24 | $32.5M | $143.3K | ||
| Q3 24 | $45.0M | $144.3K | ||
| Q2 24 | $45.0M | $146.6K | ||
| Q1 24 | $45.0M | — |
| Q4 25 | $-33.7M | $11.1M | ||
| Q3 25 | $-4.1M | $10.2M | ||
| Q2 25 | $-72.6M | $9.7M | ||
| Q1 25 | $-60.9M | $9.7M | ||
| Q4 24 | $-60.2M | $8.8M | ||
| Q3 24 | $-45.4M | $7.9M | ||
| Q2 24 | $-35.5M | $7.7M | ||
| Q1 24 | $-36.3M | $8.8M |
| Q4 25 | $160.4M | $16.2M | ||
| Q3 25 | $163.6M | $15.4M | ||
| Q2 25 | $93.7M | $12.9M | ||
| Q1 25 | $102.2M | $13.0M | ||
| Q4 24 | $101.4M | $13.7M | ||
| Q3 24 | $110.0M | $11.4M | ||
| Q2 24 | $117.6M | $11.0M | ||
| Q1 24 | $129.5M | $12.7M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.5M | $934.8K |
| Free Cash FlowOCF − Capex | $-8.6M | $906.4K |
| FCF MarginFCF / Revenue | -65.7% | 11.1% |
| Capex IntensityCapex / Revenue | 0.7% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.33× |
| TTM Free Cash FlowTrailing 4 quarters | $-53.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.5M | $934.8K | ||
| Q3 25 | $-12.6M | $-739.2K | ||
| Q2 25 | $-7.9M | $194.4K | ||
| Q1 25 | $-23.4M | $-169.9K | ||
| Q4 24 | $-6.5M | $1.0M | ||
| Q3 24 | $-11.9M | $897.3K | ||
| Q2 24 | $-7.0M | $-336.6K | ||
| Q1 24 | $-10.4M | $-912.8K |
| Q4 25 | $-8.6M | $906.4K | ||
| Q3 25 | $-12.9M | $-747.6K | ||
| Q2 25 | $-8.0M | — | ||
| Q1 25 | $-23.5M | $-258.2K | ||
| Q4 24 | $-6.5M | $941.1K | ||
| Q3 24 | $-12.0M | — | ||
| Q2 24 | $-7.0M | $-394.9K | ||
| Q1 24 | $-10.4M | $-922.1K |
| Q4 25 | -65.7% | 11.1% | ||
| Q3 25 | -100.6% | -10.9% | ||
| Q2 25 | -80.2% | — | ||
| Q1 25 | -269.9% | -3.7% | ||
| Q4 24 | -54.8% | 12.2% | ||
| Q3 24 | -88.3% | — | ||
| Q2 24 | -35.0% | -6.1% | ||
| Q1 24 | -86.4% | -14.3% |
| Q4 25 | 0.7% | 0.3% | ||
| Q3 25 | 1.8% | 0.1% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 1.5% | 1.3% | ||
| Q4 24 | 0.1% | 0.9% | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.2% | 0.9% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | — | 1.33× | ||
| Q3 25 | — | -2.21× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.29× | ||
| Q4 24 | — | 1.59× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -6.80× | ||
| Q1 24 | — | -1.17× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AQST
Segment breakdown not available.
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
